Management of Comorbid Conditions in Heart Failure. A Review

Medical Clinics of North America

Volumn 96, Issue 5, 2012, Pages 975-985

  Nagarajan, Vijaiganesh ^a   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Co morbid conditions; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ROSUVASTATIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE;

ALZHEIMER DISEASE; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; BRONCHIECTASIS; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COST BENEFIT ANALYSIS; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DRUG EFFICACY; ERYTHROPOIESIS; EXERCISE TOLERANCE; EYE DISEASE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LACTIC ACIDOSIS; MEDICARE; MICROANGIOPATHY; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SLEEP DISORDERED BREATHING; SYSTOLIC HEART FAILURE; TACHYCARDIA; WEIGHT GAIN;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84866169928     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.07.006     Document Type: Review

References (65)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
2. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):480-486.
3. Braunstein J.B., Anderson G.F., Gerstenblith G., et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003, 42(7):1226-1233.
4. Wong C.Y., Chaudhry S.I., Desai M.M., et al. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011, 124(2):136-143.
5. Zhang J.X., Rathouz P.J., Chin M.H. Comorbidity and the concentration of healthcare expenditures in older patients with heart failure. J Am Geriatr Soc 2003, 51(4):476-482.
6. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241(19):2035-2038.
7. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321(7258):405-412.
8. Gustafsson I., Brendorp B., Seibaek M., et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004, 43(5):771-777.
9. Dries D.L., Sweitzer N.K., Drazner M.H., et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001, 38(2):421-428.
10. Solang L., Malmberg K., Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999, 20(11):789-795.
11. Bell D.S. Heart failure in the diabetic patient. Cardiol Clin 2007, 25(4):523-538. vi.
12. Eurich D.T., McAlister F.A., Blackburn D.F., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335(7618):497.
13. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011, 342:d1309.
14. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41(9):1529-1538.
15. Kerr D., MacDonald I.A., Heller S.R., et al. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 1990, 29(6):685-693.
16. Larkin R.J., Atlas S.A., Donohue T.J. Spironolactone in patients with heart failure. N Engl J Med 2000, 342(2):132-133. [author reply: 133-4].
17. Kannel W.B., Ho K., Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994, 72(Suppl 2):S3-S9.
18. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 1996, 275(20):1557-1562.
19. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265(24):3255-3264.
20. Dahlof B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338(8778):1281-1285.
21. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322(22):1561-1566.
22. Gradman A.H., Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006, 48(5):326-341.
23. Iriarte M.M., Perez Olea J., Sagastagoitia D., et al. Congestive heart failure due to hypertensive ventricular diastolic dysfunction. Am J Cardiol 1995, 76(13):43D-47D.
24. Kalantar-Zadeh K., Block G., Horwich T., et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004, 43(8):1439-1444.
25. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357(22):2248-2261.
26. Gissi-HF Investigators, Tavazzi L., Maggioni A.P., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1231-1239.
27. Molyneux S.L., Florkowski C.M., George P.M., et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 2008, 52(18):1435-1441.
28. McMurray J.J., Dunselman P., Wedel H., et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol 2010, 56(15):1196-1204.
29. Sinden N.J., Stockley R.A. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010, 65(10):930-936.
30. Bales A.C., Sorrentino M.J. Causes of congestive heart failure. Prompt diagnosis may affect prognosis. Postgrad Med 1997, 101(1):44-49. 54-6.
31. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347(3):161-167.
32. De Blois J., Simard S., Atar D., et al. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail 2010, 16(3):225-229.
33. Hole D.J., Watt G.C., Davey-Smith G., et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996, 313(7059):711-715. [discussion: 715-6].
34. Godtfredsen N.S., Osler M., Vestbo J., et al. Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. J Epidemiol Community Health 2003, 57(6):412-416.
35. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125(6):2309-2321.
36. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, (4). CD003566.
37. Kasai T., Bradley T.D. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol 2011, 57(2):119-127.
38. Gami A.S., Pressman G., Caples S.M., et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004, 110(4):364-367.
39. Gottlieb D.J., Yenokyan G., Newman A.B., et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation 2010, 122(4):352-360.
40. Wang H., Parker J.D., Newton G.E., et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007, 49(15):1625-1631.
41. Javaheri S., Caref E.B., Chen E., et al. Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med 2011, 183(4):539-546.
42. Bradley T.D., Logan A.G., Kimoff R.J., et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005, 353(19):2025-2033.
43. Arzt M., Floras J.S., Logan A.G., et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007, 115(25):3173-3180.
44. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52(10):818-827.
45. Tang Y.D., Katz S.D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113(20):2454-2461.
46. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010, 31(15):1872-1880.
47. Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361(25):2436-2448.
48. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117(4):526-535.
49. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361(21):2019-2032.
50. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347(5):305-313.
51. Poirier P., Giles T.D., Bray G.A., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113(6):898-918.
52. Oreopoulos A., Padwal R., Kalantar-Zadeh K., et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008, 156(1):13-22.
53. Kenchaiah S., Gaziano J.M., Vasan R.S. Impact of obesity on the risk of heart failure and survival after the onset of heart failure. Med Clin North Am 2004, 88(5):1273-1294.
54. Mehra M.R., Uber P.A., Park M.H., et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004, 43(9):1590-1595.
55. Polidori M.C., Marvardi M., Cherubini A., et al. Heart disease and vascular risk factors in the cognitively impaired elderly: implications for Alzheimer's dementia. Aging (Milano) 2001, 13(3):231-239.
56. Vogels R.L., Scheltens P., Schroeder-Tanka J.M., et al. Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail 2007, 9(5):440-449.
57. Zuccala G., Cattel C., Manes-Gravina E., et al. Left ventricular dysfunction: a clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997, 63(4):509-512.
58. Zuccala G., Onder G., Marzetti E., et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005, 26(3):226-233.
59. Rutledge T., Reis V.A., Linke S.E., et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006, 48(8):1527-1537.
60. Plotsky P.M., Owens M.J., Nemeroff C.B. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998, 21(2):293-307.
61. Jiang W., Alexander J., Christopher E., et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001, 161(15):1849-1856.
62. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160(14):2101-2107.
63. Jacob S., Sebastian J.C., Abraham G. Depression and congestive heart failure: are antidepressants underutilized?. Eur J Heart Fail 2003, 5(3):399-400.
64. Jiang W., O'Connor C., Silva S.G., et al. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J 2008, 156(3):437-444.
65. Angermann C.E., Gelbrich G., Stork S., et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 2007, 9(12):1212-1222.